FDA-Approved APHEXDA® (motixafortide)

Large plus symbol with an image of an older man and young girl inside it

Achieve stem cell collection targets in multiple myeloma (MM) in fewer apheresis sessions¹*

APHEXDA is indicated in combination with filgrastim^† to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.¹

*GENESIS study: APHEXDA + filgrastim vs placebo + filgrastim.

^†Commonly referred to as granulocyte colony-stimulating factor (G-CSF).

Medicine bottle

About APHEXDA

Explore the design and results of the GENESIS study

Syringe

Dosing & Administration

Learn step-by-step details on how to dose APHEXDA

Hand with a heart sitting on the palm

BioLineRx Connect

Find out how this comprehensive program supports eligible patients prescribed APHEXDA

Download APHEXDA Resources

Dosing and Administration Guide

Patient Brochure

Prescribing Information

Caduceus symbol which represents healing

Understand the Challenges of Mobilization

Discover how mobilization strategies may help patients meet center-specific standards for stem cell collection in order to proceed to autologous stem cell transplantation (ASCT).²

Man with text bubble to illustrate a BioLineRx representative

Connect With a Representative

Find out how APHEXDA could help your patients with MM

References: 1. APHEXDA. Prescribing information. BioLineRx Ltd; 2023. 2. Chhabra S, Callander N, Watts NL, et al. Transplant Cell Ther. 2023;29(3):174.e1-174.e10.

Indication

APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Important Safety Information

Contraindications

APHEXDA is contraindicated in patients with a history of serious hypersensitivity reactions to motixafortide.

Warnings and precautions

Anaphylactic Shock and Hypersensitivity Reactions: Anaphylactic shock and hypersensitivity reactions have occurred. Premedicate all patients with a triple drug premedication regimen that includes an H1-antihistamine, an H2 blocker, and a leukotriene inhibitor approximately 30-60 minutes prior to each dose of APHEXDA. Administer APHEXDA in a setting where personnel and therapies are immediately available for treatment of anaphylaxis and other systemic reactions. Monitor patients for 1 hour following APHEXDA administration and manage reactions promptly. Patients receiving negative chronotropic drugs (e.g., beta-blockers) may be more at risk for hypotension in the event of a hypersensitivity reaction and these drugs, when appropriate, should be replaced with non-chronotropic drugs.
Injection Site Reactions: Injection site reactions (73%) including pain (53%), erythema (27%), and pruritus (24%) have occurred. Severe reactions occurred in 9% of patients. Premedicate with an analgesic premedication (e.g., acetaminophen) prior to each APHEXDA dose. Use analgesic medication and local treatments post-dose, as needed.
Tumor Cell Mobilization in Patients with Leukemia: For the purpose of hematopoietic stem cell (HSC) mobilization, APHEXDA may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, APHEXDA is not intended for HSC mobilization and harvest in patients with leukemia.
Leukocytosis: Administering APHEXDA in conjunction with filgrastim increases circulating leukocytes as well as HSC populations. Monitor white blood cell counts during APHEXDA use.
Potential for Tumor Cell Mobilization: When APHEXDA is used in combination with filgrastim for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied.
Embryo-fetal Toxicity: Based on its mechanism of action, APHEXDA can cause fetal harm. Advise pregnant women of the potential risk to the fetus. Verify pregnancy status in females of reproductive potential prior to initiating treatment with APHEXDA and advise use of effective contraception during treatment and for 8 days after the final dose.

Adverse Reactions

The most common adverse reactions (incidence >20%) in patients treated with APHEXDA were injection site reactions [73%, including pain (53%), erythema (27%), pruritus (24%)]; pruritus (38%); flushing (33%); back pain (21%).

USE IN SPECIFIC POPULATIONS

Pregnancy: Please see the important information in Warnings and Precautions under Embryo-fetal Toxicity.

Lactation: There are no data on the presence of motixafortide in human milk, the effects on the breastfed child, or the effects on milk production. Advise females that breastfeeding is not recommended during treatment with APHEXDA and for 8 days after the final dose.

Pediatric Use: The safety and effectiveness of APHEXDA have not been established in pediatric patients.

Please see full Prescribing Information.